Thromboprophylaxis in Outpatients with COVID-19
Author Information
Author(s): Di Vece Davide, Valgimigli Marco, Barnathan Elliot, Connors Jean M., Cools Frank, Held Ulrike, Kakkar Ajay K., Piazza Gregory, Spirk David, Virdone Saverio, Kucher Nils, Barco Stefano
Primary Institution: University Medicine Greifswald
Hypothesis
Does primary thromboprophylaxis improve outcomes in symptomatic outpatients with COVID-19?
Conclusion
Thromboprophylaxis in symptomatic COVID-19 outpatients reduced the risk of venous thromboembolism but had no impact on hospitalization or death.
Supporting Evidence
- Thromboprophylaxis was associated with lower rates of venous thromboembolism.
- The overall low absolute risk reduction suggests routine use may not be warranted.
- No significant difference in hospitalization or death rates was observed.
- Three patients experienced major bleeding, with no significant increase in risk from thromboprophylaxis.
Takeaway
Giving blood thinners to people with COVID-19 who are not in the hospital can help prevent blood clots, but it doesn't really help them avoid going to the hospital or dying.
Methodology
A systematic review and meta-analysis of randomized controlled trials comparing prophylactic-dose anticoagulation with placebo or standard care in symptomatic outpatients with COVID-19.
Potential Biases
Potential biases due to the variability in study designs and lack of external adjudication for some outcomes.
Limitations
The studies included were heterogeneous in demographics, clinical characteristics, and types of anticoagulants used.
Participant Demographics
Median age ranged from 44 to 61 years, with 44% to 61% women across studies.
Statistical Information
P-Value
0.28 for VTE risk reduction
Confidence Interval
95% CI, 0.08-0.94 for VTE
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website